Private biotechs in Switzerland raised CHF833 million (US$1.002 billion) in 2024, driving an overall increase in capital investment in the sector to $3 billion, up from $2.4 billion in 2023.

The biopharma job market likely won’t turn around until 2026, according to two industry experts. Both cited a need for more ...

Set against a backdrop of barren biotech investment, Vivo Capital has secured $740m to back preclinical and clinical-stage ...

California investment firm Vivo Capital has secured $740 million in commitments to be aimed at preclinical- and ...

With long development timelines and high burn rates, biotech companies must navigate capital markets with precision.

Now is the time for the biotechnology sector to ask for big changes to the FDA, NIH, reimbursement, intellectual property and ...

Biosimilars are gaining traction as competitors aim to capture market share from branded biologics such as Humira and ...

As with pharmaceutical and healthcare companies, investing in American biotech stocks comes with the same degree of regulatory risk. All treatments need to approval from the Food & Drugs ...

Tom Brady reacts with pride — and a bit of humor Brady, a minority owner of the Las Vegas Raiders and now an emerging force in the biotech investment space, couldn’t hold back his excitement.

New figures have confirmed that the UK’s biotech sector received a massive boost from the COVID-19 pandemic last year, with investment levels soaring to £2.8 billion ($3.8 billion) from a level ...

The U.S.-based biotechnology company is also known for its ambitious goal of bringing back the extinct woolly mammoth by 2028. This dire wolf pup is among the first of its species born in around ...